ANTI-CLEC2D ANTIBODIES AND METHODS OF USE THEREOF

The present application disclosure relates to anti-CLEC2D ( CLEC2D encodes the gene for the Lectin Like Transcript-1 -LLT1- protein which is a functional ligand for the human NKR-P1A receptor) antibodies and related compositions and methods of use thereof. These antibodies are used as therapeutics,...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: SINDHE, Kirthana Mysore Vasudevarao, CHAKRABARTY, Subhra Prakash, Prachi, RAMESH, Rao Shreesha, LAHIRI, Pallavi, MAITY, Sunit, RAO, Sahana Bhima, DUBEY, Ashvini Kumar, MARKANDA, Nikitha, BHATTACHARJEE, Sanghamitra, GHOSH, Maloy, HALAN, Vivek, NATARAJAN, Bairavabalakumar, SRIVASTAVA, Shruti, MUNIRAJU, Yogendra Manjunath Bangalore, SHENOY, Bharath Ravindra, DIKEY, Bhagyashree, RODRIGUES, Kavitha Iyer, TIWARI, Anurag, MURUGESAN, Sathyabalan
Format: Patent
Sprache:eng ; fre
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The present application disclosure relates to anti-CLEC2D ( CLEC2D encodes the gene for the Lectin Like Transcript-1 -LLT1- protein which is a functional ligand for the human NKR-P1A receptor) antibodies and related compositions and methods of use thereof. These antibodies are used as therapeutics, and in prognostic and diagnostic applications in various cancers and other diseases. La présente invention concerne de nouveaux anticorps anti-CLEC2D (CLEC2D code pour le gène pour la protéine de transcription-1-LLT1 de type lectine qui est un ligand fonctionnel pour le récepteur de NKR-P1A humain) et des compositions associées ainsi que leurs méthodes d'utilisation. Ces anticorps servent d'agents thérapeutiques, et dans des applications de pronostic et de diagnostic de divers cancers et d'autres maladies.